Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis - New therapeutical opportunities;Rola cytokin z rodziny czynnika martwicy nowotworu w przebiegu reumatoidalnego zapalenia stawów - Nowe możliwości terapii

Polski Merkuriusz Lekarski

Volumn 22, Issue 130, 2007, Pages 300-304

  Kmieć, Zbigniew ^a   SokoŁowska, Iwona ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Osteolysis; Osteoprotegerin; Receptor activator of nuclear factor B (RANK); Receptor activator of nuclear factor B ligand (RANKL); Rheumatoid arthritis; Therapy

Indexed keywords

LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; IMMUNOLOGY; METABOLISM; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; BONE RESORPTION; HUMANS; LIGANDS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; TUMOR NECROSIS FACTORS;

EID: 34249700032     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Adamopoulos I.E., Sabokbar A.P., Carr A.J. i wsp.: Synovial fluid macrophages are capable of osteoclast formation and resorption. J. Pathol., 2006, 208, 35-43.
2. Bekker P.J., Holloway D., Nakanishi A. i wsp.: The effect of a single dose of osteoprotegerin inpostmenopausal women. J. Bone. Miner. Res., 2001, 16, 348-360.
3. Bekker P.J., Holloway D.L., Rasmussen A.S. i wsp.: A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone. Miner. Res., 2004, 19, 1059-1066.
4. Body J.J., Greipp P., Coleman R.E. i wsp.:A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer, 2003, 97, 887-892.
5. Boyce B.F., Li P., Yao Z. i wsp.: TNFa and pathologic bone resorption. Keio. J. Med., 2005, 54, 127-131.
6. Catrina A.I., Af Klint E., Ernestam S. i wsp.: Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum., 2006, 54, 76-81.
7. Crotti T.N., Crotti T., Smith M.D. i wsp.: Receptor activator NFkappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann. Rheum. Dis., 2002, 61, 1047-1054.
8. Gaffen S.L.: Biology of recently discovered cytokines: interleukin-17 - a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res. Ther., 2004, 6, 240-247.
9. Haynes D.R., Crotti T.N., Loric M. i wsp.: Osteoprotegerin and receptor activatorof nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology, 2001, 40, 623-630.
10. Hofbauer L.C., Lacey D.L., Dunstan C.R. i wsp.: Interleukin-1beta and tumor necrosis factor-alpha, but not interteukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 1999, 25, 255-259.
11. Hsu H., Lacey D., Dunstan C. i wsp.: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by Osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA. 1999, 96, 3540-3545.
12. Kirkham B.W., Lassere M.N., Edmonds J.P. i wsp.: Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum., 2006, 54, 1122-1131.
13. Lacey D.L., Timms E., Tan H.L. i wsp.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93, 165-176.
14. Lee C.K., Lee E.Y., Chung S.M. i wsp.: Effects of disease-modifying antirheumatic drugs and anti-inflammatory cytokines on human osteoclastogenesis through interaction with RANK, osteoprotegerin, and RANKL. Arthritis Rheum., 2004, 50, 3831-3843.
15. Manolagas S.C.: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev., 2000, 21, 115-137.
16. Miranda-Carus M., Benito-Miguel M., Balsa A. i wsp.: Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum., 2006, 54, 1151-1164.
17. O'gradaigh D., Ireland D., Bord S. i wsp.: Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor, interleukin 1, and receptor activator of nuclear factor B ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis., 2004, 63, 354-359.
18. Ritchlin C.T., Haas-Smith S.A., Li P. i wsp.: Mechanisms of TNF-alpha and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest., 2003, 111, 821-831.
19. Rivollier A., Mazzorana M., Tebib J. i wsp.: Immature dendritic cell trans-differentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood, 2004, 104, 4029-4037.
20. Simonet W.S., Lacey D.L., Dunstan C.R. i wsp.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89, 309-319.
21. 2 synthase to bone resorption. J. Cell. Physiol., 2003, 197, 348-356.
22. Takahashi N., Udagawa N., Suda T.: A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun., 1999, 256, 449-455.
23. Tanaka S., Takahashi N., Udagawo N. i wsp.: Macrophage colony stimulating factor is indispensible for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest., 1993, 91, 257-265.
24. Teitelbaum S.L., Ross F.P.: Genetic regulation of osteoclast development and function. Nat. Rev. Genet., 2003, 4, 638-649.
25. Van Lieshout A.W., Barrera P., Smeets R.L. i wsp.: Inhibitor of TNF- during maturation of dendritic cells results in the development of semi-mature cells. Ann. Rheum. Dis., 2005, 64, 408-414.
26. Vis M., Haavardsholm E.A., Haugeberg G. i wsp.: Evaluation of bone mineral density, bone metabolism, Osteoprotegerin and RANKL serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2006.
27. Walsh N.C., Crotti T.N., Goldring S.R. i wsp.: Rheumatic diseases: the effects of inflammation on bone. Immunol. Rev., 2005, 208, 228-251.
28. Welsing P.M., Landewe R.B., Van Riel PL. i wsp.: The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum., 2004, 50, 2082-2093.
29. Xing L., Boyce B.F.: Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem. Biophys. Res. Commun., 2005, 328, 709-720.
30. Xing L., Schwartz E.M., Boyce B.F.: Osteoclast precursors, RANKL, RANK, and osteoimmunology. Immunol. Rev., 2005, 208, 19-29.